Lopinavir/Ritonavir Ranbaxy 100 mg/25 mg apvalkotās tabletes Latvija - latviešu - Zāļu valsts aģentūra

lopinavir/ritonavir ranbaxy 100 mg/25 mg apvalkotās tabletes

ranbaxy uk ltd., united kingdom - lopinavirum, ritonavirum - apvalkotās tabletes - 100 mg/25 mg

Ketanov 10 mg mutē disperģējamās tabletes Latvija - latviešu - Zāļu valsts aģentūra

ketanov 10 mg mutē disperģējamās tabletes

ranbaxy uk ltd., united kingdom - ketorolaka trometamols - mutē disperģējamās tabletes - 10 mg

Xylometazoline/Ipratropium bromide Ranbaxy 0,5 mg/0,6 mg/ml deguna aerosols, šķīdums Latvija - latviešu - Zāļu valsts aģentūra

xylometazoline/ipratropium bromide ranbaxy 0,5 mg/0,6 mg/ml deguna aerosols, šķīdums

ranbaxy (poland) sp. z o.o., poland - xylometazolini hydrochloridum, ipratropii bromidum - deguna aerosols, šķīdums - 0,5 mg/0,6 mg/ml

Xylometazolini hydrochloridum Ranbaxy 0,5 mg/ml deguna aerosols, šķīdums Latvija - latviešu - Zāļu valsts aģentūra

xylometazolini hydrochloridum ranbaxy 0,5 mg/ml deguna aerosols, šķīdums

ranbaxy (poland) sp.z.o.o., poland - ksilometazolīna hidrohlorīds - deguna aerosols, šķīdums - 0,5 mg/ml

Xylometazolini hydrochloridum Ranbaxy 1 mg/ml deguna aerosols, šķīdums Latvija - latviešu - Zāļu valsts aģentūra

xylometazolini hydrochloridum ranbaxy 1 mg/ml deguna aerosols, šķīdums

ranbaxy (poland) sp.z.o.o., poland - ksilometazolīna hidrohlorīds - deguna aerosols, šķīdums - 1 mg/ml

Ketanov 10 mg apvalkotās tabletes Latvija - latviešu - Zāļu valsts aģentūra

ketanov 10 mg apvalkotās tabletes

sun pharmaceutical industries europe b.v., netherlands - ketorolacum trometamolum - apvalkotā tablete - 10 mg

Lopinavir/Ritonavir Sun 200 mg/50 mg apvalkotās tabletes Latvija - latviešu - Zāļu valsts aģentūra

lopinavir/ritonavir sun 200 mg/50 mg apvalkotās tabletes

sun pharmaceutical industries europe b.v., netherlands - lopinavirum, ritonavirum - apvalkotā tablete - 200 mg/50 mg

Sitagliptin SUN Eiropas Savienība - latviešu - EMA (European Medicines Agency)

sitagliptin sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Sitagliptin / Metformin hydrochloride Sun Eiropas Savienība - latviešu - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , triple kombinēto terapiju), kā palīglīdzekli, lai diētu un vingrošanu pacientiem nepietiekami kontrolē par to maksimālā pieļaujama devu metformīns un sulfonilurīnvielas pamata. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Atosiban SUN Eiropas Savienība - latviešu - EMA (European Medicines Agency)

atosiban sun

sun pharmaceutical industries europe b.v. - atosiban (as acetate) - priekšlaicīga dzimtene - citi ginekoloģiskie līdzekļi - atosiban ir norādīts, lai aizkavētu draudošo pirms termiņa dzimšanas grūtniecēm pieaugušām sievietēm ar:regulāras dzemdes kontrakcijas vismaz 30 sekunžu ilgumu, ātrumu ≥ 4 par 30 minūtēm;dzemdes kakla dilatācija ir no 1 līdz 3 cm (0-3 par nulliparas) un effacement ≥ 50%;gestācijas vecums no 24 līdz 33 pabeigta nedēļas;normālu augļa sirdsdarbība.